At Marinus Pharmaceuticals, our passionate team of experts is constantly innovating with the aim to drastically improve lives affected by seizure disorders. This program allows qualified patients to receive the investigational drug ganaxolone for CDD. We are dedicated to maximizing the value of ganaxolone as we investigate its potential in a number of diversified indications.
Ganaxolone, through its validated GABAA mechanism, has opportunities in orphan indications and in chronic and acute care settings. We are developing breakthrough therapies in status epilepticus, tuberous sclerosis complex, and CDKL5 deficiency disorder. We are conducting high quality research in-house, with our scientific advisory board and external consultants to ensure patients are receiving innovative and safe treatment options.
Ganaxolone, through its validated GABAA mechanism, has opportunities in orphan indications and in chronic and acute care settings. We are developing breakthrough therapies in status epilepticus, tuberous sclerosis complex, and CDKL5 deficiency disorder. We are conducting high quality research in-house, with our scientific advisory board and external consultants to ensure patients are receiving innovative and safe treatment options.
Services
Marinus is committed to improving the lives of patients living with seizure disorders. We are developing an investigational drug, ganaxolone, which is an innovative and much needed potential treatment option for children and adults. Ganaxolone, our leading drug candidate, is designed to exhibit anti-epileptic, anxiolytic, antidepressant, and sedative activity by virtue of its GABAA receptor modulating properties.
Ganaxolone, our lead clinical stage drug candidate, possesses enhanced activity at receptors for the neurotransmitter GABA (gamma-aminobutyric acid), the major regulator of excessive activity of neurons in the brain. We believe it may have the potential to modulate the abnormalities that underlie some of the most severe seizure disorders.
Marinus Pharmaceuticals, Inc. is committed to forwarding science and research in a range of seizure disorders, and having a positive impact on the lives of patients and caregivers. We strive to develop safe, effective, and innovative therapies, and provide support and education to the rare disease community.
Marinus Pharmaceuticals supports Expanded Access Programs (EAPs) as an important way of allowing patients access to investigational medicines prior to FDA approval. Expanded access, sometimes called "compassionate use, " is the use of an investigational medicine (i.e., one that has not been approved by the Food and Drug Administration (FDA)) by a patient who can not be enrolled in a clinical trial.
Marinus is dedicated to developing new therapies for patients with rare seizure disorders, and to serving patients, their families and the healthcare professionals who care for them.
Consistent with our mission to bring innovative medicines to patients with serious or life-threatening conditions, we are focused on conducting the clinical trials necessary to gain regulatory approvals to make our medicines available broadly to patients as quickly as possible.Clinical trials are an essential part of collecting the necessary data on safety and efficacy to support regulatory approval.
Consistent with our mission to bring innovative medicines to patients with serious or life-threatening conditions, we are focused on conducting the clinical trials necessary to gain regulatory approvals to make our medicines available broadly to patients as quickly as possible.Clinical trials are an essential part of collecting the necessary data on safety and efficacy to support regulatory approval.
Reviews
Be the first to review Marinus Pharmaceuticals.
Write a Review
